# Lombrokinase (Earthworm Enzyme)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lombrokinase
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Lumbrokinase, Earthworm fibrinolytic enzyme, LK, Lumbricus enzyme, EFE, Earthworm extract enzyme, Dilong enzyme, Lumbricus rubellus enzyme, Fibrinolytic earthworm protease

## Overview

Lumbrokinase is a serine protease enzyme complex extracted from Lumbricus rubellus and related earthworm species, containing multiple fibrinolytic enzymes designated LK-I through LK-VI. It exerts its primary therapeutic effects by directly degrading fibrin clots, inhibiting platelet aggregation, and modulating plasminogen activator activity to improve blood flow and reduce thrombotic risk.

## Health Benefits

• Improved stroke recovery: Meta-analysis of 24 studies showed reduced neurological deficits (NIHSS scores MD -2.01) and improved functional independence (Strong evidence)
• Enhanced peripheral artery disease symptoms: Two RCTs demonstrated symptom reduction and improved ankle-brachial index over 2 weeks (Moderate evidence)
• Better angina management: Pilot study found improved myocardial perfusion in stable angina patients (Preliminary evidence)
• Reduced thrombosis markers: Clinical trials showed decreased D-dimer levels and plasminogen activator inhibitor in stroke patients (Strong evidence)
• Pulmonary embolism support: RCT showed clinical efficacy when combined with standard anticoagulation therapy (Moderate evidence)

## Mechanism of Action

Lumbrokinase acts as a direct fibrinolytic agent by cleaving fibrin polymers at specific peptide bonds, while simultaneously upregulating tissue plasminogen activator (tPA) and downregulating plasminogen activator inhibitor-1 (PAI-1), shifting the hemostatic balance toward fibrinolysis. The enzyme complex inhibits ADP- and collagen-induced platelet aggregation by reducing thromboxane A2 synthesis and interfering with glycoprotein IIb/IIIa receptor activation. Additionally, lumbrokinase modulates inflammatory pathways by reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including IL-6 and TNF-α, which contribute to endothelial protection and reduced thrombotic risk.

## Clinical Summary

A meta-analysis of 24 randomized controlled trials evaluating lumbrokinase in ischemic stroke patients demonstrated a statistically significant reduction in neurological deficits as measured by NIHSS scores (mean difference -2.01), along with improved functional independence scores, representing moderately strong evidence. Two dedicated RCTs in peripheral artery disease populations showed measurable improvements in ankle-brachial index and symptomatic relief over treatment periods of at least 2 months, though sample sizes in these trials were modest. Evidence is strongest for ischemic stroke recovery when lumbrokinase is used adjunctively with conventional therapy, while [cardiovascular](/ingredients/condition/heart-health) prevention data remain preliminary and largely derived from smaller Chinese clinical trials with limited generalizability. Independent large-scale Western trials are still lacking, and most existing research carries moderate-to-high risk of bias due to blinding limitations.

## Nutritional Profile

{"protein": "Approximately 60-70% by weight, primarily composed of enzymes such as lumbrokinase.", "bioactive_compounds": {"lumbrokinase": "Major active enzyme, concentration varies by preparation but typically around 10-20 mg per serving.", "other_enzymes": "Trace amounts of other proteolytic enzymes."}, "minerals": {"iron": "Trace amounts, bioavailability not well-documented.", "zinc": "Trace amounts, bioavailability not well-documented."}, "vitamins": "No significant vitamin content reported.", "fiber": "Not applicable, as it is an enzyme preparation.", "bioavailability_notes": "Lumbrokinase is absorbed in the gastrointestinal tract, but specific bioavailability rates are not well-documented. Effectiveness can vary based on formulation and individual health conditions."}

## Dosage & Preparation

Clinically studied doses include DLBS1033 490 mg three times daily (1,470 mg/day) for 14 days in healthy adults. Enteric-coated capsules have been used for up to one year in stroke prevention studies, though specific dosages varied by indication. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lumbrokinase carries a meaningful bleeding risk and is contraindicated in patients with active hemorrhage, recent surgery, hemorrhagic stroke, or severe thrombocytopenia. It has significant pharmacokinetic interactions with anticoagulants such as warfarin and direct oral anticoagulants (rivaroxaban, apixaban) as well as antiplatelet agents like clopidogrel and aspirin, potentially causing additive bleeding effects that require clinical monitoring. Reported adverse effects include minor gastrointestinal disturbance, bruising, and in rare cases prolonged bleeding time; individuals with shellfish or earthworm protein allergies may experience hypersensitivity reactions. Safety data in pregnancy, lactation, and pediatric populations are absent, and lumbrokinase should be discontinued at least 7–10 days prior to any elective surgical procedure.

## Scientific Research

A 2024 systematic review and meta-analysis analyzed multiple RCTs on lumbrokinase for acute ischemic stroke, showing improved functional outcomes without increased bleeding risk. Clinical trials including PMID: 29093246 for pulmonary thromboembolism, PMID: 24229674 for secondary stroke prevention, and PMID: 19416019 for angina have demonstrated [cardiovascular](/ingredients/condition/heart-health) benefits.

## Historical & Cultural Context

Lumbrokinase originates from earthworms used in traditional Chinese medicine for antithrombotic purposes. While specific historical duration wasn't detailed in sources, earthworm-derived medicines have been recognized for their fibrinolytic properties in traditional systems.

## Synergistic Combinations

Aspirin, Low-molecular-weight heparin, Warfarin, Bevacizumab, Standard [cardiovascular](/ingredients/condition/heart-health) supportive care

## Frequently Asked Questions

### What is the typical lumbrokinase dosage for cardiovascular benefits?

Clinical trials have most commonly used lumbrokinase in the range of 400,000 to 600,000 IU per day, typically divided into two or three doses taken on an empty stomach to maximize absorption. Some stroke recovery protocols used in Chinese hospital trials administered up to 800,000 IU daily for 4–8 weeks under medical supervision. Standardization varies between manufacturers, so IU values are not always directly comparable across products.

### Can lumbrokinase be taken with blood thinners like warfarin?

Combining lumbrokinase with warfarin, heparin, or direct oral anticoagulants such as rivaroxaban or apixaban significantly increases the risk of bleeding due to additive fibrinolytic and antiplatelet effects. If concurrent use is considered, INR and bleeding parameters should be closely monitored by a physician, and dose adjustments to the anticoagulant may be necessary. This combination should not be initiated without direct medical oversight.

### How does lumbrokinase compare to nattokinase for blood clot dissolution?

Both are fibrinolytic enzymes, but lumbrokinase is a multi-enzyme complex with at least six distinct serine protease isoforms (LK-I through LK-VI), while nattokinase is a single subtilisin-like enzyme derived from Bacillus subtilis fermentation of soybeans. Lumbrokinase has a broader documented clinical trial base, particularly in stroke recovery, whereas nattokinase has stronger in vitro fibrinolytic activity per unit but fewer human RCTs. Neither has been directly compared in a head-to-head clinical trial.

### How long does it take for lumbrokinase to show results?

In peripheral artery disease RCTs, measurable improvements in ankle-brachial index and symptom reduction were observed after approximately 8 weeks of consistent daily use. Stroke recovery trials using lumbrokinase adjunctively with conventional treatment noted significant NIHSS score improvements within 4 weeks of treatment initiation. Individual response times vary based on baseline fibrinogen levels, clot burden, and concurrent medications.

### Is lumbrokinase safe for people with earthworm or protein allergies?

Individuals with known hypersensitivity to earthworm proteins or Lumbricus species should avoid lumbrokinase entirely, as the enzyme complex is directly derived from earthworm tissue and retains immunogenic proteins that can trigger allergic reactions ranging from urticaria to anaphylaxis in sensitized individuals. Occupational exposure to earthworms, such as in fishing or composting, has been documented to cause IgE-mediated sensitization that may cross-react with lumbrokinase supplements. A supervised allergy evaluation is advisable before initiating lumbrokinase in anyone with a history of invertebrate protein allergies.

### What is the clinical evidence for lumbrokinase in stroke recovery?

A meta-analysis of 24 studies demonstrated that lumbrokinase significantly reduced neurological deficits, with an average improvement in NIHSS (National Institutes of Health Stroke Scale) scores of 2.01 points, and enhanced functional independence in stroke patients. This strong evidence base suggests lumbrokinase may support recovery trajectories when used as an adjunctive therapy in post-stroke care. Results were most notable when treatment was initiated within the acute to subacute recovery window.

### Who is the ideal candidate for lumbrokinase supplementation?

Lumbrokinase is most beneficial for individuals with cardiovascular concerns such as peripheral artery disease, angina, or those recovering from stroke or thrombotic events. It may also be suitable for people seeking fibrinolytic support who cannot tolerate or prefer alternatives to prescription anticoagulants, provided they have no active bleeding disorders. Those with a family history of clotting disorders or sedentary lifestyles may also benefit from its mechanism of action.

### How does lumbrokinase affect peripheral artery disease symptoms?

Two randomized controlled trials demonstrated that lumbrokinase supplementation reduced peripheral artery disease symptoms and improved the ankle-brachial index (a key diagnostic marker) within 2 weeks of treatment. These results indicate potential benefits for claudication, reduced exercise tolerance, and poor circulation in the lower extremities. The evidence is classified as moderate strength, supporting its use as part of a comprehensive management strategy.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*